San Antonio Breast Cancer Symposium 2025 Press Program

UT Health San Antonio and the American Association for Cancer Research (AACR) are co-sponsors of the San Antonio Breast Cancer Symposium 2025 (SABCS) at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Each year, SABCS features the latest research on the biology, etiology, prevention, diagnosis, and treatment of breast cancer and premalignant breast disease, including data from late-breaking clinical trials. Each year, the symposium attracts thousands of basic researchers, physician-scientists, clinical investigators, breast care providers, and advocates from around the world.

Press conference 1

SABCS Program Director Kate Lathrop, MD, UT Health San Antonio, moderated the first press conference on Wednesday, December 10.

The following studies were presented:

Adding Tucatinib to First-line Maintenance Therapy Delayed Disease Progression in HER2-positive Metastatic Breast Cancer in HER2CLIMB-05 Trial

• Presented by Erika Hamilton, MD, Sarah Cannon Research Institute

Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers

• Presented by Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center

Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial

• Presented by Aditya Bardia, MD, MPH, University of California, Los Angeles Jonsson Comprehensive Cancer Center

VIEW PRESS CONFERENCE 1